Canaccord lowered the firm’s price target on Teladoc to $25 from $28 and keeps a Buy rating on the shares. The firm said they would characterize the copany’s Q1 results as decent with both earnings and adjusted-EBITDA coming in ahead of consensus estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Options Volatility and Implied Earnings Moves Today, April 25, 2024
- Optum virtual care exit ‘clear positive’ for Teladoc, says BofA
- UnitedHealth’s Optum closing virtual care business, Endpoints says
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Teladoc Health Provides Updated Start Time for First Quarter 2024 Earnings Call on April 25
